Copper reverses cardiomyocyte hypertrophy through vascular endothelial growth factor-mediated reduction in the cell size

Journal of Molecular and Cellular Cardiology

Volumn 45, Issue 1, 2008, Pages 106-117

  Zhou, Yang ^a   Jiang, Youchun ^a   Kang, Y James ^a  

^a University of Louisville School of Medicine   (United States)

Author keywords

Cardiomyocytes; Cell size; Copper; Hypertrophy; Primary cultures; VEGF

Indexed keywords

ALPHA ACTIN; ATRIAL NATRIURETIC FACTOR; COPPER SULFATE; HISTONE; HYPOXIA INDUCIBLE FACTOR 1; MYOSIN HEAVY CHAIN BETA; PHENYLEPHRINE; VASCULOTROPIN; VASCULOTROPIN ANTIBODY;

ANIMAL CELL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CELL CULTURE; CELL CYCLE; CELL DIVISION; CELL LABELING; CELL SIZE; CONCENTRATION RESPONSE; CONTROLLED STUDY; FLOW CYTOMETRY; HEART MUSCLE CELL; HEART VENTRICLE HYPERTROPHY; NEWBORN; NICK END LABELING; NONHUMAN; PRIORITY JOURNAL; PROTEIN CONTENT; RAT;

ANIMALS; ANTIDOTES; APOPTOSIS; BIOLOGICAL MARKERS; CARDIOMEGALY; CARDIOTONIC AGENTS; CELL SIZE; CELLS, CULTURED; COPPER SULFATE; DOSE-RESPONSE RELATIONSHIP, DRUG; MICE; MYOCYTES, CARDIAC; PHENYLEPHRINE; RATS; RATS, SPRAGUE-DAWLEY; TIME FACTORS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

RATTUS;

EID: 45549106004     PISSN: 00222828     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.yjmcc.2008.03.022     Document Type: Article

References (29)

1. Jiang Y., Reynolds C., Xiao C., Feng W., Zhou Z., Rodriguez W., et al. Dietary copper supplementation reverses hypertrophic cardiomyopathy induced by chronic pressure overload in mice. J Exp Med 204 (2007) 657-666
2. Witte K.K.A., Nikitin N.P., Parker A.C., von Haehling S., Volk H.D., Anker S.D., et al. The effect of micronutrient supplementation on quality-of-life and left ventricular function in elderly patients with chronic heart failure. Eur Heart J 26 (2005) 2238-2244
3. Klevay L.M. Heart failure improvement from a supplement containing copper. Eur Heart J 27 (2006) 117
4. Shiojima I., Sato K., Izumiya Y., Schiekofer S., Ito M., Liao R., et al. Disruption of coordinated cardiac hypertrophy and angiogenesis contributes to the transition to heart failure. J Clin Invest 115 (2005) 2108-2118
5. Walsh K., and Shiojima I. Cardiac growth and angiogenesis coordinated by intertissue interactions. J Clin Invest 117 (2007) 3176-3179
6. Nör J.E., Christensen J., Mooney D.J., and Polverini P.J. Vascular endothelial growth factor (VEGF)-mediated angiogenesis is associated with enhanced endothelial cell survival and induction of Bcl-2 expression. Am J Pathol 154 (1999) 375-384
7. Alon T., Hemo I., Itin A., Pe'er J., Stone J., and Keshet E. Vascular endothelial growth factor acts as a survival factor for newly formed retinal vessels and has implications for retinopathy of prematurity. Nat Med 1 (1995) 1024-1028
8. Hoffmann P., Richards D., Heinroth-Hoffmann I., Mathias P., Wey H., and Toraason M. Arachidonic acid disrupts calcium dynamics in neonatal rat cardiac myocytes. Cardiovasc Res 30 (1995) 889-898
9. Siddiqui R.A., Shaikh S.R., Kovacs R., Stillwell W., and Zaloga G. Inhibition of phenylephrine-induced cardiac hypertrophy by docosahexaenoic acid. J Cell Biochem 92 (2004) 1141-1159
10. Zhou Y., Jiang Y., and Kang Y.J. Copper inhibition of hydrogen peroxide-induced hypertrophy in embryonic rat cardiac H9c2 cells. Exp Biol Med 232 (2007) 385-389
11. Yoshioka J., Prince R.N., Huang H., Perkins S.B., Cruz F.U., MacGillivray C., et al. Cardiomyocyte hypertrophy and degradation of connexin43 through spatially restricted autocrine/paracrine heparin-binding EGF. Proc Natl Acad Sci U S A 102 (2005) 10622-10627
12. Barron M., Gao M., and Lough J. Requirement for BMP and FGF signaling during cardiogenic induction in non-precardiac mesoderm is specific, transient, and cooperative. Dev Dyn 218 (2000) 383-393
13. Ikezoe T., Yang J., Nishioka C., Tasaka T., Taniguchi A., Kuwayama Y., et al. A novel treatment strategy targeting Aurora kinases in acute myelogenous leukemia. Mol Cancer Ther 6 (2007) 1851-1857
14. Tsujita Y., Muraski J., Shiraishi I., Kato T., Kajstura J., Anversa P., et al. Nuclear targeting of Akt antagonizes aspects of cardiomyocyte hypertrophy. Proc Natl Acad Sci U S A 103 (2006) 11946-11951
15. Winer J., Jung C.K., Shackel I., and Williams P.M. Development and validation of real-time quantitative reverse transcriptase-polymerase chain reaction for monitoring gene expression in cardiac myocytes in vitro. Anal Biochem 270 (1999) 41-49
16. Izumiya Y., Shiojima I., Sato K., Sawyer D.B., Colucci W.S., and Walsh K. Vascular endothelial growth factor blockade promotes the transition from compensatory cardiac hypertrophy to failure in response to pressure-overload. Hypertension 47 (2006) 887-893
17. Friehs I., Moran A.M., Stamm C., Choi Y.H., Cowan D.B., McGowan F.X., et al. Promoting angiogenesis protects severely hypertrophied hearts from ischemic injury. Ann Thorac Surg 77 (2004) 2004-2011
18. Simpson P., and Savion S. Differentiation of rat myocytes in single cell cultures with and without proliferating nonmyocardial cells. Cross-striations, ultrastructure, and chronotropic response to isoproterenol. Circ Res 50 (1982) 101-116
19. Martin F., Linden T., Katschinski D.M., Oehme F., Flamme I., Mukhopadhyay C.K., et al. Copper-dependent activation of hypoxia-inducible factor (HIF)-1: implications for ceruloplasmin regulation. Blood 105 (2005) 4613-4619
20. Ahmed Z., Idowu B.D., and Brown R.A. Stabilization of fibronectin mats with micromolar concentrations of copper. Biomaterials 20 (1999) 201-209
21. Hu G.F. Copper stimulates proliferation of human endothelial cells under culture. J Cell Biochem 69 (1998) 326-335
22. Shimojo N., Jesmin S., Zaedi S., Otsuki T., Maeda S., Yamaguchi N., et al. Contributory role of VEGF overexpression in endothelin-1-induced cardiomyocyte hypertrophy. Am J Physiol Heart Circ Physiol 293 (2007) H474-H481
23. Sano M., Minamino T., Toko H., Miyauchi H., Orimo M., Qin Y., et al. P53-induced inhibition of HIF-1 causes cardiac dysfunction during pressure overload. Nature 446 (2007) 444-448
24. Shyu K.G., Liou J.Y., Wang B.W., Fang W.J., and Chang H. Carvedilol prevents cardiac hypertrophy and overexpression of hypoxia-inducible factor-1 and vascular endothelial growth factor in pressure-overloaded rat heart. J Biomed Sci 12 (2005) 409-420
25. Friehs I., Barillas R., Vasilyev N.V., Roy N., McGowan F.X., and del Nido P.J. Vascular endothelial growth factor prevents apoptosis and preserves contractile function in hypertrophied infant heart. Circulation 114 1 Suppl (2006) I290-I295
26. Seetharam L., Gotoh N., Maru Y., Neufeld G., Yamaguchi S., and Shibuya M. A unique signal transduction from FLT tyrosine kinase, a receptor for vascular endothelial growth factor VEGF. Oncogene 10 (1995) 135-147
27. Waltenberger J., Claesson-Welsh L., Siegbahn A., Shibuya M., and Heldin C.H. Different signal transduction properties of KDR and Flt1, two receptors for vascular endothelial growth factor. J Biol Chem 269 (1994) 26988-26995
28. Kroll J., and Waltenberger J. The vascular endothelial growth factor receptor KDR activates multiple signal transduction pathways in porcine aortic endothelial cells. J Biol Chem 272 (1997) 32521-32527
29. Sen C.K., Khanna S., Venojarvi M., Trikha P., Ellison E.C., Hunt T.K., et al. Copper-induced vascular endothelial growth factor expression and wound healing. Am J Physiol Heart Circ Physiol 282 (2002) 1821-1827